Kiniksa Pharmaceuticals International, PLC reports results for the quarter ended June 30 - Earnings Summary

Kiniksa Pharmaceuticals International

28/07/2026 13:26

Kiniksa Pharmaceuticals International, PLC KNSA.OQ reported quarterly adjusted earnings of 30 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of 23 cents.  The mean expectation of eight analysts for the quarter was for earnings of 30 cents per share. Wall Street expected results to range from 25 cents to 38 cents per share.
Revenue rose 55.4% to $243.60 million from a year ago; analysts expected $225.46 million. 
Kiniksa Pharmaceuticals International, PLC's reported EPS for the quarter was 30 cents​.
The company reported quarterly net income of $25.43 million.
Kiniksa Pharmaceuticals International, PLC shares had fallen by 0.6% this quarter and gained 54.0% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 3.9% in the last three months.​ 
In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy" 
Wall Street's median 12-month price target for Kiniksa Pharmaceuticals International, PLC is $72.00, about 11.8% above its last closing price of $63.54
This summary was machine generated from LSEG data July 28 at 12:26 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
0.30
0.30
Met
Mar. 31 2026 
0.20
0.27
Beat
Dec. 31 2025 
0.37
0.17
Missed
Sep. 30 2025 
0.32
0.23
Missed